Status:

TERMINATED

Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)

Lead Sponsor:

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborating Sponsors:

Merck Sharp & Dohme LLC

Celgene Corporation

Conditions:

Peripheral T-Cell Non-Hodgkin's Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

A standard therapy is neither established in first-line patients nor in relapsed patients with PTCL, and there is still an unmet medical need to identify novel efficacious and safe therapy regimens. ...

Eligibility Criteria

Inclusion

  • Patients with relapsed PTCL according to WHO criteria who have received max. two previous treatments for PTCL
  • Age ≥ 18 years.
  • Adequate bone marrow function i.e. absolute neutrophile count of \> 1000/µl and thrombocytes \> 75,000/µl.
  • Alkaline phosphatase and transaminases ≤ 2,5 x upper limit of normal (ULN)
  • Total bilirubin ≤ 2,5 x ULN
  • Creatinine clearance ≥ 50 ml/min
  • Female subjects of childbearing potential† must: Understand that the study medication could have an expected teratogenic risk and agree to use, and be able to comply with, effective contraception and agree to have a medically supervised pregnancy test
  • Male subjects must agree to use condoms and agree not to donate semen

Exclusion

  • Prior history of malignancies, other than PTCL, unless the subject has been free of the disease for ≥ 3 years
  • Prior allogeneic bone marrow transplant or plans to undergo autologous/ allogeneic bone marrow transplant within 4 weeks of the initiation of vorinostat administration
  • Prior treatment with a HDAC inhibitor
  • Prior treatment with Lenalidomide (patients previously treated with Thalidomide may be enrolled)
  • Known history of Deep Vein Thrombosis (DVT) and/ or pulmonary embolism (PE)

Key Trial Info

Start Date :

September 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2012

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00972842

Start Date

September 1 2009

End Date

July 1 2012

Last Update

December 24 2013

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie

Innsbruck, Tyrol, Austria, A-6020

2

Krankenhaus der Elisabethinen Linz

Linz, Austria, A-4010

3

Krankenhaus der Stadt Linz

Linz, Austria, A-4020

4

Universitaetsklinik f. Innere Medizin III

Salzburg, Austria, A-5020